- $92.42m
- $49.24m
- $7.95m
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics Q1 net loss narrows on lower R&D spends
Brief: Coya Therapeutics Inc - Files For Resale Of Up To 2.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Coya Therapeutics Provides A Corporate Update And Reports Fiscal 2025 Financial Results
Brief: Coya Therapeutics Announces Results Of Investigator-Initiated Study Of Ld Il-2 And Ctla4-Ig
Brief: Coya Therapeutics Announces U.S. FDA Acceptance Of Investigational New Drug Application For COYA 302
Brief: Coya Therapeutics Receives Clinical Trial Application Acceptance From Health Canada
Coya Therapeutics' Q3 net loss narrows
U.S. STOCKS ON THE MOVE-GrafTech, Nextracker, Alpha and Omega, Coinbase
U.S. STOCKS ON THE MOVE-GrafTech, Nextracker, Alpha and Omega
U.S. STOCKS ON THE MOVE-Cipher Mining, Kura, GrafTech
U.S. STOCKS ON THE MOVE-Alphabet, Ford, Procter & Gamble
Coya Therapeutics plunges after upsized $20 million share sale
Brief: Coya Therapeutics Announces Completion Of Patient Enrollment
Brief: Coya’s COYA 303 Shows Promising CNS Anti-Inflammatory Effects & Treg-Boosting Effects in Preclinical Inflammation Model
U.S. STOCKS ON THE MOVE-Artelo Biosciences, Coya, Vital Energy